Afrigen Biologics Secures $6.2M Grant to Pioneer Next-Gen Vaccine Adjuvants in Africa

Afrigen Biologics (Pty) Ltd is proud to announce a remarkable funding milestone, having successfully raised 6,200,000 to further its mission of transforming healthcare in Africa. Based in Cape Town, Afrigen Biologics and Vaccines is a pioneering biotechnology company strategically supported by Avacare Healthcare Group and the Industrial Development Corporation (IDC) of South Africa. Founded in 2014 by visionary leaders Steven G. Reed (PhD) and Erik Iverson (JD, LLM) of the Infectious Diseases Research Institute in Seattle, the company has swiftly become a driving force in the development and production of adjuvants and essential biologicals. This significant capital injection will be utilized to bolster key areas of the business strategy, including advancing product development, expanding capabilities in bulk adjuvant manufacturing, and enhancing the supply and distribution network of its critical health products. By investing in state-of-the-art research and forging robust international partnerships alongside local capacity building, Afrigen is uniquely positioned to meet Africa’s healthcare challenges head-on. At the heart of this progress is the groundbreaking, first-ever adjuvant production and formulation technology centre on the continent, established in collaboration with IDRI—a world authority in next generation vaccine adjuvant development. This funding will further empower the centre’s work in creating adjuvants that not only prevent diseases but also exhibit therapeutic properties, thereby conferring enhanced potency and durability to vaccines. With this investment, Afrigen continues to pave the way for innovative, locally developed biological solutions, ensuring that the healthcare needs of both humans and animals are met with cutting-edge science and unwavering dedication.